I-Mab accelerating lemzoparlimab's global development

4 December 2020

China-based immuno-oncology-focussed biotech I-Mab Biopharma (Nasdaq: IMAB) today announced the advancement of clinical development of its highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the USA and China, achieving milestones as planned.

The company is progressing its US combination trial (NCT03934814), studying lemzoparlimab in combination with Rituxan (rituximab) and Keytruda (pembrolizumab) in dose expansion cohorts in advanced non-Hodgkin lymphoma (NHL) and solid tumors, respectively. The combination study with Rituxan will enroll NHL patients from both the USA and China. Top-line results from this study are expected next year.

I-Mab is also poised to advance lemzoparlimab into late-stage clinical development in China. China’s Center for Drug Evaluation (CDE) accepted I-Mab’s Investigational New Drug (IND) application to advance to a combination trial with azacitidine (AZA) in untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK